# Leal Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leal-therapeutics

- Industry: Biotechnology
- Headquarters: Worcester, US
- Website: https://lealtx.com/
- Total disclosed funding: $105M
- Latest round: Series A (Aug 18, 2026)
- Investors on record: 8

## About

Based in Massachusetts, US, and founded in 2021 by CEO Asa Abeliovich, Leal Therapeutics, Inc. specializes in creating therapeutics for central nervous system disorders. In August 2026, Leal Therapeutics, Inc. raised USD 30 million in series A funding from Alexandria Venture Investments, Chugai Venture Fund, Euclidean Capital, Newpath Partners, OrbiMed Advisors, PhiFund Ventures, SV Health Investors, and Eli Lilly and Co. The round was part larger USD 60 million series A funding. The company provides a wide range of therapeutic products aimed at CNS disorders, including lipid metabolism-targeting LTX-002 for ALS and Alzheimer’s, presynaptic glutamate modulator LTX-001 for schizophrenia and ALS, and complement pathway inhibitor LTX-003 for Alzheimer’s and FTD. Additionally, the firm also provides investigational ASO-based therapies like LTX-004 for lipid trafficking in dementia-related conditions and LTX-005 targeting NMDAR in refractory epilepsy and treatment-resistant depression. The company's solutions are marketed primarily in North America and select regions in Europe, targeting diverse clientele across public and private healthcare institutions. Leal Therapeutics, Inc. generates revenue through a combination of subscription-based models and direct service contracts with healthcare providers. Clients enter into annual subscription agreements granting them access to the company's software platforms and continuous updates, featuring tiered pricing plans that cater to different sizes of healthcare organizations. The company plans to use the August 2026 funding for schizophrenia and amyotrophic lateral sclerosis drug clinical development, and central nervous system drug pipeline clinical development.

## Funding rounds

- Series A, Aug 18, 2026, $30M — OrbiMed Advisors, Alexandria Venture Investments, SV Health Investors, Eli Lilly & Company, Euclidean Capital, Newpath Partners, PhiFund Ventures, Chugai Venture Fund
- Series A, Aug 27, 2025, $30M — OrbiMed Advisors, Alexandria Venture Investments, SV Health Investors, Euclidean Capital, Newpath Partners, PhiFund Ventures, Chugai Venture Fund
- Series A, Oct 30, 2024, $45M — OrbiMed Advisors, Alexandria Venture Investments, Euclidean Capital, Newpath Partners, PhiFund Ventures, Chugai Venture Fund

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Euclidean Capital — Series A
- Newpath Partners (https://capitalatlas.ai/funds/newpath-partners) — Series A
- PhiFund Ventures (https://capitalatlas.ai/funds/phifund-ventures) — Series A
- Chugai Venture Fund (https://capitalatlas.ai/funds/chugai-venture-fund) — Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- Eli Lilly & Company — Series A